2226: Hemogenyx CEO on positive progress with leukemia drug

from The Vox Markets Podcast · host Vox Markets Podcast

Watch on YouTubeHemogenyx #HEMO has been given clearance to proceed with the next stage of testing in regard to its HG-CT1 therapy, which is designed to treat leukemia. Hemogenyx's chief executive Vladislav Sandler joins us to talk about the implications of continuing the trials, how they will be structured, and widened with the addition of testing for a group of 12-18 year olds.

NOW PLAYING

0:00 8:42

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Vox Markets Podcast?

This episode is 8 minutes long.

When was this The Vox Markets Podcast episode published?

This episode was published on October 30, 2025.

What is this episode about?

Can I download this The Vox Markets Podcast episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.

URL copied to clipboard!